Usually when I'm optimistic about something, the Gods are

New Post Public Reply Private Reply Replies (2) Message Board
homerbedloe
461
Usually when I'm optimistic about something, the Gods are quick to smack me back into place with a clear message regarding how wrong I could be, and in fact, was. But I'm going to do this anyway - so once you read this, stand at least 15 feet away from me to avoid being collateral damage when I'm struck by lightning. Talk about social distancing...yeesh. LOL

OK, we've all been waiting on pins and needles for BARDA news and the impact it will have on our pps. Well, what if we look at what happens if BARDA and the CV19 vaccine doesn't get off the ground? Are we still ok staying with GNBT?

My take (DUCK!) is that we will be good with or without BARDA, although probably better with than without. Here's my logic (RJS or Doc, please feel free to correct me if my "science" or terminology is wrong - hopefully, you all will get the message I'm trying to make anyway). IF the CV19 vaccine isn't picked up by anybody, we still have taken huge steps down a road that has never been taken before. A process was planned, contractors were secured and execution of the process was begun; peptides were simulated and identified as most likely to elicit an immune response; combos of those peptides are being tested against blood from actual virus victims to determine if the immune response can be generated. If it all stops right there, we have proven that there is a process to develop a synthetic vaccine, even if we don't know yet if it works. That's all good, but here is the best part...

We know Joe is doing everything he can to get NGIO listed. We also know he has lined up somewhere between $50 and $120 million in various packages to secure non-grant funding. We know that when NGIO is made public, there will be a public offering that will raise another $100 to $200 million for GNBT. So with or without BARDA, we will have cash to go forward.

Some of that money will go to the diabetes clinic/work, some will go to Altucel, some to Excellegan. NGIO money will be used for further AE37 research with TNBC, as well as prostate work. With all that going, I'm confident GNBT will now have avenues to raise further money with only minor dilution (if necessary), and some of that money will be available to resurrect the vaccine study. Maybe it will be for another novel CV??, the Swine flu that has been identified recently or maybe it will be for something as mundane as the annual flu. But if the process does work, and I'm confident Dr. EvH would not have stuck with it this long if he didn't truly believe it would, GNBT/NGIO will be able to develop a provable vaccine for some virus that they will be able to show the world.

In the meantime, the other funding will allow all the other initiatives to be pursued, which will start bringing tangible revenue to GNBT. The NGIO IPO should also put a huge asset on GNBT's books that will eventually be recognized in the pps. At that point, I think a lot of this uncertainty will be in our collective rear view mirrors, and we'll all be talking about what's the NEXT big thing for GNBT.

Would I prefer getting a BARDA grant today or tomorrow so the CV19 work can proceed full steam ahead? Damn right I would, because I think Joe and Co are going down the right vaccine path with a long term vaccine, while the RNA/mRNA vaccines will probably be temporary bandaids. I'm tired of worrying about going to the store or shaking hands with a neighbor (yep, I'm on the thin edge of that high risk group). And yes, I admit to wanting the financial reward from a successful GNBT vaccine, but I think with or without BARDA, we will get that reward over the next year or so.

Hey, there may even be an upside to not getting a BARDA grant - can you imagine if GNBT can pull off the vaccine development anyway, how stupid and politically motivated BARDA and the whole process will look? I don't think there will be enough middle fingers available in the world to shoot at the BARDA folks, if that happens. I know I'll be throwing a few, with a big-ass grin on my face.

OK, now stand clear while the lightning is thrown. Just hoping Zeus (or whoever is in charge of lightning retribution these days) has lost their touch (or eyesight) and isn't that great of shot. Probably another reason to socially distance yourselves from me right now.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 24

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 557

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
Breakthrough T1D Pushes Global T1D Awareness Forward

Updated Category News Views 353

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 265

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 21

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 278

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 550

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 287

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 21

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 28

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading

Top 5 Most Recently Viewed Articles

Bank of France's Villeroy Talks About Fiscal Deficit Strategies

Updated Category News Views 84

Bank of France's Perspective on France's Budget Deficit In a recent conversation, Francois Villeroy de Galhau, the head of the Bank of France, addressed the challenges France faces concerning its budget deficit. He pointed out that while hitting a 3% GDP deficit in three years might be unrealistic, there is still a chance for success within five years if the right...

Continue Reading
Vantiva Reports Strong Financial Growth in H1 2025

Updated Category News Views 273

Vantiva Financial Performance Review for H1 2025 Strong EBITDA Growth and Positive Cash Flow Vantiva, known for its significant role in the connectivity sector, has unveiled its financial outcomes for the first half of 2025. The results reflect considerable growth, driven by a strategic transformation plan aimed at enhancing operational efficiency and customer...

Continue Reading
Invisors Achieves 4632 Rank on Inc. 5000 Fastest Growing List

Updated Category News Views 170

Invisors Recognized on the Inc. 5000 List Invisors has achieved remarkable recognition by securing the 4632nd position on the esteemed Inc. 5000 list, celebrating the fastest-growing private companies in America. This achievement marks the fifth time that Invisors has made its way onto this prestigious ranking, reflecting not only the organization's strong revenue growth...

Continue Reading
Invivyd Showcases PEMGARDA™ Advances at IDWeek 2024

Updated Category News Views 395

Invivyd Outlines Significant Findings on PEMGARDA™ at IDWeek 2024 Invivyd, Inc. (Nasdaq: IVVD), a dedicated biopharmaceutical enterprise, is set to present groundbreaking findings related to its investigational monoclonal antibody, pemivibart, at the much-anticipated IDWeek 2024 conference. Here, researchers and healthcare professionals will gather in Los Angeles to...

Continue Reading
Netcompany Reports Strong Results and Future Outlook

Updated Category News Views 637

Continued Growth and Investment in Future Prospects Netcompany has showcased promising performance, particularly in the second quarter of 2025, with a reported revenue growth of 3.9%, totaling DKK 1,714.9 million. This aligns with a steady trajectory that the company has maintained over recent periods, emphasizing its strong market presence and resilience even as it faces...

Continue Reading